Inovio Pharmaceuticals (MEX:INO) Profitability Rank: 0 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INO Inovio Pharmaceuticals Inc MEX:INO
39 GF Score
Price MXN12.10
GF Value MXN3.86
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Profitability Rank?

Inovio Pharmaceuticals has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Inovio Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2026 was %. As of today, Inovio Pharmaceuticals's Piotroski F-Score is 1.


Inovio Pharmaceuticals Profitability Rank Related Terms


MEX:INO vs TELO, ELTX, ALPS: Profitability Rank Comparison

For the Biotechnology subindustry, Inovio Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals Profitability Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Profitability Rank falls into.


MEX:INO
39GF Score
Inovio Pharmaceuticals Inc MEX:INO
Profitability Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Inovio Pharmaceuticals has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Inovio Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=-324.988 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Inovio Pharmaceuticals has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Inovio Pharmaceuticals Inc operating margin has been in a 5-year decline. The average rate of decline per year is -116.6%.

4. Consistency of the profitability

5. Predictability Rank

Is Inovio Pharmaceuticals (MEX:INO) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of MXN12.10 is trading 213.5% above its estimated GF Value™ of MXN3.86. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEX:INO:

  • Profitability Rank: 0
  • GF Value™: MXN3.86 vs. price of MXN12.10 (213.5% above fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the MEX:INO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inovio Pharmaceuticals Business Description

Other Exchanges INO:USA0A43:UKGBM:Germany
Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
39GF Score

Get the complete analysis for MEX:INO

Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN12.10
Price
MXN3.86
GF Value